# Facial Flushing, Racing Heart, Gut Pain, and Crashing After Meals: Could Excess Gut Serotonin Be Driving Mast Cell Activation?

> The hidden connection between serotonin overload, Prevotella copri, impaired serotonin clearance, and the gut–immune–nervous system.

- **Author:** Mohammed Attallah (BiomeLogic)
- **Published:** 2026-10-22
- **Category:** SIBO
- **Tags:** mast-cell-activation, gut-health, sertonin, mcas, histamine, mast-cells, dysautonomia, bile-acids, hormones, mitochondria, butyrate, microbiome, serotonin, cardiovascular
- **Canonical URL:** https://biomelogic.net/articles/facial-flushing-racing-heart-gut
- **License:** CC BY-NC 4.0 — please cite "Mohammed Attallah, BiomeLogic" with link to https://biomelogic.net/articles/facial-flushing-racing-heart-gut.

---

During a recent consultation, I was reviewing a complex case involving gastrointestinal symptoms, neuroimmune sensitivity, and concerns about excessive serotonin activity in the gut. One of the things that caught my attention was a medication the individual was taking called cyproheptadine, also known as Periactin. This medication is particularly interesting because it does more than block histamine. It also antagonizes certain serotonin receptors, particularly within the 5-HT2 family, and has anticholinergic properties, meaning it can interfere with acetylcholine signaling in the nervous system and gastrointestinal tract.

As I continued reviewing the individual’s history and microbiome findings, I noticed something else that made me want to investigate the relationship more closely. The intestinal microbiome analysis showed an elevated abundance of a bacterium called *Prevotella copri*. This bacterium has some interesting metabolic characteristics, particularly its ability to produce compounds such as acetate and succinate, which can influence intestinal signaling, inflammation, and epithelial function.

That combination raised an important question for me. What if some cases of apparent serotonin excess involve more than increased serotonin production? What if the intestinal environment has also changed in a way that interferes with the body’s ability to clear serotonin after it is released, while simultaneously making nearby nerves and immune cells more sensitive?

The medication itself does not establish that serotonin is elevated, and finding increased *Prevotella copri* does not prove that the bacterium is responsible for the symptoms. Nevertheless, I found the combination interesting enough to investigate the biochemical pathways connecting microbial metabolism, serotonin regulation, intestinal inflammation, and mast-cell signaling.

The deeper I examined these mechanisms, the more interested I became in the possibility that some gastrointestinal reactions may involve a disturbance in the communication between the intestinal microbiome, enterochromaffin cells, mast cells, and the nervous system.

Imagine eating a relatively normal meal and suddenly experiencing facial flushing, abdominal discomfort, nausea, a racing heart, dizziness, or an overwhelming feeling that your nervous system has become overstimulated. Some individuals develop urgent diarrhea or severe intestinal cramping, while others experience profound fatigue and brain fog. There are also people who describe feeling dramatically worse after a bowel movement, sometimes experiencing palpitations, shaking, weakness, or an urgent need to lie down.

These symptoms can have several different medical explanations, including food allergies, inflammatory bowel disease, disorders of gut–brain interaction, dysautonomia, and mast-cell disorders. They should not automatically be attributed to serotonin excess. But I believe serotonin physiology deserves more attention because it sits at the intersection of gastrointestinal movement, sensory signaling, microbial metabolism, and communication with the nervous system.

What interests me is whether, in certain individuals, the problem is not simply the food they are eating but the physiological environment that receives that food.

## Why Serotonin in the Gut Is So Important

Most people associate serotonin with depression, anxiety, mood regulation, and the brain. However, approximately 90% of the body’s serotonin is produced in the gastrointestinal tract, primarily by specialized epithelial cells called enterochromaffin cells.

These cells are scattered throughout the intestinal lining and function as biological sensors. They respond to mechanical stretching, nutrients, microbial metabolites, bile acids, and other chemical changes occurring within the gastrointestinal environment. When stimulated, they can release serotonin, also known as 5-hydroxytryptamine or 5-HT, which communicates with nearby intestinal nerves and other cells to coordinate normal digestive physiology.

Serotonin helps regulate intestinal motility, fluid secretion, nausea signaling, and visceral sensation. When food enters the gut, enterochromaffin cells participate in the communication required to move intestinal contents forward and coordinate the appropriate digestive responses. This is entirely normal, and we need serotonin signaling for healthy gastrointestinal function.

The important issue is how tightly that signaling is regulated. Serotonin must be produced in appropriate amounts, released at the correct time, interact with the right receptors, and subsequently be cleared from the extracellular environment. If any part of this sequence becomes disrupted, the resulting physiological response can change significantly.

This is why I think it is important to distinguish between **excessive serotonin production and excessive serotonin signaling**. They are not necessarily the same thing. An individual could produce a relatively normal amount of serotonin but experience prolonged receptor stimulation because the mechanisms responsible for removing serotonin have become less effective. Alternatively, the amount of serotonin may not be particularly unusual, but the sensory nerves responding to it may have become unusually sensitive.

To understand this difference, we need to examine one of the most important regulatory proteins in the intestinal serotonin system: the serotonin transporter, commonly called SERT.

## SERT: What Happens When the Gut Cannot Properly Clear Serotonin?

SERT is encoded by a gene called *SLC6A4*. Its function is to transport serotonin from the extracellular environment back into cells, helping terminate the signal after serotonin has activated its receptors.

I think of this transporter as part of the intestinal cleanup machinery. When an enterochromaffin cell releases serotonin, nearby receptors detect the molecule and initiate changes in neural signaling, intestinal movement, or secretion. But once that message has been delivered, serotonin cannot simply remain in the surrounding tissue indefinitely without potentially altering the duration of receptor activation.

SERT helps remove serotonin from that extracellular environment. The transporter uses electrochemical gradients involving sodium and chloride to move serotonin across the cellular membrane. These gradients are maintained indirectly through energy-dependent processes, including the sodium-potassium ATPase, which requires ATP to preserve normal cellular ion balance.

After serotonin enters the cell, it can undergo additional metabolism through enzymes including monoamine oxidase A, or MAO-A. This pathway contributes to the breakdown of serotonin into metabolites that ultimately include 5-hydroxyindoleacetic acid, commonly abbreviated as 5-HIAA.

The distinction between these processes matters. SERT is involved in serotonin uptake, while MAO-A participates in its subsequent degradation. They represent different stages of serotonin regulation, and dysfunction in one does not automatically mean the other has stopped working.

What makes this particularly interesting is that intestinal inflammation can alter SERT expression. In inflamed intestinal tissue from people with ulcerative colitis and Crohn’s disease, reduced epithelial serotonin-transporter expression has been observed. Inflammatory mediators, including TNF-alpha, can contribute to changes in this transport system.

Now consider what this could mean physiologically. If enterochromaffin cells continue releasing serotonin but the surrounding epithelial cells become less efficient at removing it, the duration of serotonin exposure may increase. That could potentially alter gastrointestinal nerve activation, secretion, motility, and the sensitivity of the intestinal environment.

Importantly, lower SERT expression does not by itself establish that serotonin has accumulated to excessive concentrations. The final extracellular concentration depends on how much serotonin is synthesized, released, metabolized, transported, and distributed within the tissue. Nevertheless, impaired clearance offers a mechanistically different explanation for abnormal signaling, and I believe this distinction is particularly relevant when examining gastrointestinal disorders associated with inflammation.

This brought me back to the elevated *Prevotella copri* finding and whether microbial activity might contribute to the conditions that influence serotonin production and clearance.

## Prevotella copri, Acetate, LPS, and the Intestinal Serotonin Environment

*Prevotella copri*, also classified as *Segatella copri* in newer taxonomy, is a Gram-negative intestinal bacterium that can be found in healthy people. Its presence is not inherently pathological, and different strains can exhibit different metabolic and immunological characteristics. However, the organism has attracted attention because particular strains can produce metabolites capable of interacting with host physiology.

One of those metabolites is acetate, a short-chain fatty acid generated during bacterial carbohydrate fermentation. Acetate is a normal component of intestinal metabolism, but it can also participate in signaling pathways that influence host cells.

This becomes relevant to serotonin because enterochromaffin cells synthesize serotonin through an enzymatic pathway involving tryptophan hydroxylase 1, or TPH1. This enzyme carries out the rate-limiting step in peripheral serotonin synthesis, converting tryptophan into 5-hydroxytryptophan, which can then be converted into serotonin.

Microbial metabolites, including acetate, can influence TPH1 expression. This provides a mechanism through which changes in bacterial metabolism may alter serotonin synthesis without the bacteria needing to produce serotonin directly.

In other words, the microbiome may influence how much serotonin the body’s own enterochromaffin cells produce by changing the chemical signals those cells receive.

Certain acetate-producing *P. copri* strains have been associated with changes in serotonin-related metabolism, making this a reasonable relationship to investigate. However, an elevated bacterial abundance on a stool test does not tell us how much acetate is being produced, whether TPH1 is increased, or whether intestinal serotonin is actually elevated.

The second mechanism that interested me involves lipopolysaccharide, commonly referred to as LPS.

LPS is a structural component of the outer membrane of Gram-negative bacteria. Our immune system contains specialized recognition mechanisms capable of responding to particular forms of LPS, including a receptor complex involving Toll-like receptor 4, or TLR4, together with MD-2 and CD14.

When an activating LPS molecule engages this receptor complex, it can recruit intracellular adaptor proteins such as MyD88 and initiate signaling through IRAK4, TRAF6, and downstream regulatory pathways. These interactions can eventually activate NF-κB, a transcription factor involved in controlling inflammation, immune defense, and cellular stress responses.

NF-κB signaling can influence production of inflammatory cytokines, including TNF-alpha and IL-6. These molecules can alter intestinal epithelial physiology, and TNF-alpha is particularly relevant because it can contribute to reduced SERT expression.

This creates an intriguing potential connection. If changes in microbial signaling contribute to intestinal inflammation, and inflammation suppresses the proteins responsible for serotonin clearance, microbial activity could indirectly prolong serotonin signaling even without directly increasing its synthesis.

But the specific structure of the bacterial LPS matters enormously. Not all LPS molecules produce the same inflammatory response, and LPS from a characterized *P. copri* strain has shown substantially weaker TLR4 activation than classical *Escherichia coli* LPS. We therefore cannot assume that elevated *P. copri* automatically produces strong TLR4 activation or suppresses SERT.

I am interested in the broader possibility that microbial products, cytokines, and epithelial serotonin transport may become functionally connected in certain inflammatory environments.

There are also epigenetic mechanisms capable of influencing gene expression through DNA methylation and histone modifications. Proteins such as DNMT1 and HDAC1 participate in this regulation, but the specific proposal that *P. copri* permanently silences *SLC6A4* through these proteins has not been established in human intestinal tissue.

The biologically grounded question is whether microbial inflammatory signaling can contribute to an intestinal environment in which serotonin clearance becomes impaired. If that occurs alongside changes in serotonin synthesis, the effects on surrounding nerves could potentially become more pronounced.

And the story does not end with acetate and LPS, because *Prevotella copri* can also produce another interesting metabolite called succinate.

## Succinate: How Microbial Metabolism May Influence the Intestinal Barrier

Succinate is familiar to anyone who studies mitochondrial metabolism because it is an intermediate in the tricarboxylic acid cycle. However, succinate is also produced by certain intestinal bacteria during fermentation and can function as an extracellular signaling molecule.

One receptor that detects succinate is called SUCNR1, also known as GPR91. This receptor allows cells to respond to extracellular succinate and initiate downstream signaling.

A particularly interesting connection involving *P. copri* is the proposed SUCNR1–FoxM1–IL-6–STAT3 pathway. In certain intestinal models, succinate-associated signaling can influence inflammatory responses and reduce expression of proteins involved in maintaining epithelial barrier integrity, including occludin and other tight-junction components.

To understand why this matters, we need to appreciate that the intestinal lining is more than a physical barrier separating the digestive tract from the rest of the body. It is an active, metabolically demanding tissue that regulates which substances cross the epithelium and how the immune system encounters microbial products.

Adjacent epithelial cells are connected through specialized protein structures called tight junctions. These include proteins such as occludin, claudins, and scaffolding molecules like ZO-1. Together, they help regulate the movement of substances between cells.

When inflammatory signaling disrupts these structures, intestinal permeability can change. This does not mean everything inside the gut suddenly passes freely into the bloodstream, but it can alter the degree of interaction between luminal substances and the underlying mucosal immune system.

That is especially interesting because mast cells, sensory nerves, blood vessels, and other immune cells are positioned within the tissue beneath the epithelial lining.

I began considering whether microbial metabolic changes could influence several components of the intestinal environment simultaneously. Acetate may influence enterochromaffin-cell serotonin synthesis. Inflammatory cytokines may influence serotonin clearance. Succinate-associated pathways may influence epithelial barrier regulation.

If several of these processes are altered together, the resulting intestinal environment may behave differently from one in which epithelial metabolism and microbial signaling remain relatively stable.

The evidence does not establish that this entire sequence occurs in everyone with elevated *P. copri*, and the strongest causal support for the succinate pathway comes from experimental intestinal systems. Nevertheless, it provides a framework for investigating how microbial metabolites may interact with host physiology.

This leads to the next part of the relationship: the interaction between serotonin-sensitive nerves and mast cells.

## How Serotonin, Mast Cells, and Sensory Nerves May Interact

Mast cells are immune cells located throughout the gastrointestinal tract, skin, respiratory tissues, and other interfaces between the body and its environment. They contain storage compartments called granules that hold biologically active molecules such as histamine, tryptase, and chymase.

When appropriately activated, mast cells can release these preformed mediators and generate additional inflammatory compounds, including prostaglandins, leukotrienes, and cytokines.

What I find particularly interesting about intestinal mast cells is their anatomical relationship with sensory nerves. These cells can be positioned very close to nerve fibers within the intestinal mucosa, sometimes forming specialized contacts supported by adhesion molecules such as CADM1.

This proximity allows mediators released by mast cells to influence nearby nerves, while nerve-derived molecules can communicate back to mast cells. Human research examining intestinal tissue has associated mast-cell proximity to mucosal nerves with abdominal pain in individuals with irritable bowel syndrome.

Serotonin is relevant because it acts on several receptor families distributed throughout the gastrointestinal nervous system and other tissues.

The 5-HT3 receptor is particularly important in visceral sensory signaling. Unlike most serotonin receptors, it is a ligand-gated ion channel. When serotonin binds, the channel opens and allows positively charged ions to move across the membrane, producing rapid electrical effects in responsive cells.

This mechanism participates in nausea, pain signaling, and gastrointestinal sensory responses.

Another receptor, 5-HT2A, belongs to the G-protein-coupled receptor family. It typically signals through Gq proteins, which can activate an enzyme called phospholipase C-beta.

Phospholipase C-beta acts on the membrane phospholipid PIP2, producing two secondary messengers: inositol trisphosphate, or IP3, and diacylglycerol, or DAG.

IP3 interacts with receptors on the endoplasmic reticulum, allowing calcium stored within that compartment to enter the cytoplasm. DAG participates in activating protein kinase C, which helps regulate downstream cellular processes.

This pathway is important because intracellular calcium controls many secretory and inflammatory responses.

However, not every human mast-cell population expresses the same serotonin receptors, and serotonin does not universally stimulate mast-cell degranulation. Some serotonin receptor pathways can even inhibit histamine release. The proposed direct connection between excess intestinal serotonin, mast-cell 5-HT2A activation, and subsequent degranulation therefore requires careful investigation.

The more established relationship is that abnormal serotonin signaling can influence intestinal nerves, while mast-cell mediators can independently increase nerve sensitivity. These processes could potentially interact in susceptible tissue.

To understand how mast-cell activation becomes a physical inflammatory response, we need to examine the intracellular machinery that releases its stored mediators.

## The STIM1–Orai1 Calcium System and How Mast Cells Release Their Granules

One of the most fascinating aspects of mast-cell biology is the structural machinery responsible for degranulation.

Mast cells do not simply rupture or release all their contents indiscriminately. They contain carefully regulated cellular mechanisms that control the movement and fusion of secretory granules.

Calcium is a central component of this process.

During several forms of mast-cell activation, receptor signaling increases intracellular calcium. Part of that calcium initially comes from stores inside the endoplasmic reticulum, a cellular compartment that regulates protein processing and calcium storage.

When IP3 receptors open, calcium leaves the endoplasmic reticulum and enters the cytoplasm. As the calcium concentration inside the endoplasmic reticulum falls, a specialized protein called STIM1 detects the change.

STIM1 then undergoes a structural rearrangement and accumulates near regions where the endoplasmic reticulum approaches the outer cell membrane. At these junctions, STIM1 can interact directly with Orai1, a calcium-selective channel embedded in the plasma membrane.

This interaction opens a pathway that allows extracellular calcium to enter the cell. The process is called store-operated calcium entry, or SOCE.

The biological significance is that the cell can maintain calcium signaling beyond the initial release from its internal stores. This sustained calcium entry helps regulate secretion and other cellular responses.

Mast-cell membranes contain specialized cholesterol- and sphingolipid-enriched regions, often discussed as lipid rafts or membrane nanodomains. These regions can influence the spatial organization of receptors and signaling proteins, although they are dynamic rather than rigid structures, and their precise organization varies among cell types.

Once calcium-dependent signaling reaches the appropriate conditions, mast-cell granules are mobilized toward the plasma membrane. Their fusion is coordinated by proteins belonging to the SNARE family, including syntaxin-4, SNAP-23, and vesicle-associated membrane proteins such as VAMP7 and VAMP8.

These proteins help bring the granule membrane and cell membrane into close proximity. Through coordinated protein interactions, the two lipid bilayers can merge, producing a fusion pore through which granule contents enter the surrounding tissue.

Other proteins, including members of the Munc family and calcium-sensitive regulators, help coordinate this process.

The result is the release of mediators capable of influencing nearby cells. Depending on the stimulus, mast cells may release different amounts and combinations of mediators rather than completely emptying their granules.

The STIM1–Orai1 pathway is particularly interesting because it contributes to mast-cell activation through several receptor systems, including MRGPRX2. This provides a mechanistic connection between certain neuropeptides and calcium-dependent mast-cell secretion.

Whether excessive intestinal serotonin directly recruits this same pathway through 5-HT2A in human gastrointestinal mast cells remains an open question, but the downstream calcium and granule-fusion mechanisms are biologically well characterized.

And once those inflammatory mediators enter the surrounding tissue, their effects can extend beyond the mast cell itself.

## Tryptase, PAR2, and Why Normal Intestinal Movement Can Become Painful

One of the most important mediators released by mast cells is tryptase, a protease capable of modifying proteins in its surrounding environment.

Tryptase can influence signaling through protease-activated receptors, including PAR2.

PAR2 is unusual because it can be activated through proteolytic cleavage. Rather than simply binding an external signaling molecule, the receptor can be cut at a specific extracellular site, exposing a previously hidden sequence that functions as a tethered ligand.

This newly exposed segment then interacts with the receptor and initiates intracellular signaling.

In human PAR2, the canonical tethered-ligand sequence is associated with SLIGKV.

PAR2 signaling can influence epithelial cells and sensory neurons, and under certain conditions it contributes to inflammatory responses and increased nerve sensitivity. The receptor is not permanently activated after cleavage; mechanisms including desensitization, internalization, and receptor turnover help regulate its activity.

Nevertheless, repeated or sustained protease-associated signaling may contribute to an environment in which sensory nerves become hypersensitive.

Consider what this means for someone experiencing gastrointestinal pain. Under normal circumstances, intestinal stretching, gas movement, and muscular contractions produce relatively little discomfort. But if the sensory nerves have become sensitized, the same mechanical activity can generate disproportionately severe pain.

This is known as visceral hypersensitivity.

Some individuals describe a burning or raw sensation in the abdomen, while others experience severe cramping from relatively small meals or modest intestinal distension.

These sensations can be influenced by multiple mechanisms, including serotonin receptors on sensory nerves, immune mediators, epithelial inflammation, and the processing of sensory information by the central nervous system.

Mast-cell chymase and other inflammatory mediators may also influence extracellular proteins, tissue remodeling, and vascular permeability. Histamine and prostaglandins can alter vascular behavior and sensory signaling, potentially contributing to flushing, warmth, swelling, or other symptoms under appropriate conditions.

What matters is that several cell types are communicating within the same tissue. An inflammatory signal originating from an immune cell can affect a nerve, while changes in nerve activity can influence surrounding immune cells.

This brings us to another pathway that I believe deserves more attention: Substance P and MRGPRX2.

## Substance P, MRGPRX2, and the Possibility of Neuroimmune Amplification

Substance P is a neuropeptide released by certain sensory neurons. It participates in pain transmission and neurogenic inflammation and can influence the behavior of nearby immune cells.

When sensory nerves become activated, they do not always communicate exclusively toward the spinal cord and brain. Some sensory nerve fibers can also release signaling molecules locally through mechanisms involving axon reflexes.

An axon reflex occurs when electrical activity within one sensory branch propagates into neighboring branches, allowing local release of neuropeptides without requiring the conventional spinal reflex pathway.

Substance P released in this environment can interact with a mast-cell receptor called MRGPRX2.

This receptor is especially interesting because it can initiate mast-cell activation independently of the classical IgE-mediated allergy pathway.

Whereas conventional allergic reactions often involve antibodies binding to FcεRI receptors on mast cells, MRGPRX2 can respond to particular neuropeptides and other molecules through G-protein-dependent signaling.

Substance P is one of the molecules capable of engaging this pathway.

When MRGPRX2 becomes activated, downstream signaling can recruit calcium-dependent mechanisms, including components involving STIM1, and produce mast-cell mediator release.

This creates the possibility of reciprocal signaling. An activated sensory nerve releases Substance P, which stimulates nearby mast cells. Those mast cells release mediators capable of sensitizing nerves or modifying the local inflammatory environment, potentially making subsequent stimuli more noticeable or painful.

There is also an additional relationship between tachykinin signaling and gastrointestinal enteroendocrine physiology that deserves investigation, including whether Substance P acting through neurokinin receptors can modify serotonin release or synthesis under certain conditions.

However, we do not yet know whether this produces a continuous, self-sustaining serotonin-production loop in people with MCAS, IBS, or other gastrointestinal disorders.

I think the useful concept is not that the tissue necessarily becomes permanently trapped in an uncontrollable cycle, but that **immune and nervous-system signaling may become mutually amplifying under certain inflammatory conditions**.

And if the intestinal environment is already producing altered serotonin signals, that could theoretically contribute another source of sensory stimulation.

## Why Someone Might Experience Facial Flushing, Palpitations, or a Crash After Eating

Now we can begin connecting these mechanisms to the symptoms people actually experience.

When food enters the gastrointestinal tract, normal digestive activity triggers changes in motility, secretion, gut hormones, blood flow, and autonomic signaling. Enterochromaffin cells participate in this process through serotonin release.

If intestinal sensory nerves have become hypersensitive, normal changes associated with digestion may produce exaggerated symptoms. These might include nausea, urgency, cramping, or significant abdominal discomfort.

If mast-cell mediators are also involved, their effects on vascular permeability, smooth muscle, and sensory signaling may contribute additional symptoms such as flushing or abdominal discomfort.

Autonomic physiology adds another layer. Eating normally increases blood flow to the gastrointestinal circulation, and the body must adjust cardiovascular regulation to maintain blood pressure and cerebral perfusion. In individuals with certain forms of dysautonomia, these adjustments may be less effective, resulting in postprandial tachycardia, lightheadedness, fatigue, or cognitive symptoms.

These processes can overlap, making it difficult to determine the cause from symptoms alone.

I find post-bowel-movement reactions especially interesting because some individuals describe profound weakness, tremulousness, palpitations, brain fog, or an intense need to lie down after defecation.

Bowel movements can produce significant autonomic and cardiovascular changes, particularly during straining. Vasovagal reflexes, fluctuations in venous return, blood pressure changes, and underlying autonomic dysfunction can all contribute.

It is possible that intestinal sensory hypersensitivity or immune-mediated signaling may worsen the experience in certain individuals, but the claim that post-bowel-movement crashes are caused by serotonin directly triggering massive mast-cell degranulation has not been established.

The same caution applies to other symptoms sometimes attributed to neuroimmune activation, including bladder irritation, skin prickling, heat intolerance, adrenaline-like surges, or cognitive exhaustion.

These symptoms can involve overlapping neural, inflammatory, or autonomic pathways, but none of them independently proves excess intestinal serotonin or MCAS.

What I believe deserves investigation is whether altered intestinal signaling acts as one contributor within a broader physiological network in a subset of patients.

## Butyrate, Mitochondrial Metabolism, and the Environment Surrounding Serotonin-Producing Cells

This brings me to another area I have been studying extensively: the relationship between microbial butyrate production and intestinal epithelial metabolism.

Butyrate is a short-chain fatty acid produced when certain intestinal bacteria ferment dietary fibers and other substrates reaching the colon.

Several bacterial groups contribute to its production, including *Faecalibacterium prausnitzii*, *Roseburia intestinalis*, *Anaerostipes* species, and other anaerobic organisms.

These bacteria often depend on one another through a process called cross-feeding. One organism may generate acetate or lactate, while another uses those compounds to synthesize butyrate.

As a result, butyrate production depends not only on whether a particular bacterial species is present but also on the metabolic relationships within the microbial ecosystem.

Butyrate is particularly important because mature colonocytes, the epithelial cells lining the colon, can use it as a major energy substrate.

Once transported into the colonocyte, butyrate can undergo mitochondrial metabolism through activation to butyryl-CoA, subsequent oxidation, acetyl-CoA generation, and entry into the tricarboxylic acid cycle. This contributes to oxidative phosphorylation and ATP production.

But the significance of this process extends beyond cellular energy.

As colonocytes oxidize butyrate, they consume oxygen. This helps maintain the relatively low-oxygen environment close to the colonic epithelium that supports obligately anaerobic bacteria.

Butyrate also influences cellular signaling pathways associated with PPARγ, epithelial differentiation, inflammatory regulation, and gene expression.

This creates an important reciprocal relationship. The microbiome produces metabolites that influence epithelial physiology, while epithelial metabolism helps maintain the environmental conditions supporting particular microbial communities.

During intestinal inflammation, epithelial differentiation, mitochondrial function, oxygen consumption, and microbial ecology may change together. This can create conditions in which the intestinal environment becomes less favorable for some anaerobic organisms, potentially influencing the overall balance of microbial metabolites.

Something I frequently consider in my work is the difference between butyrate production and butyrate utilization.

A microbiome may contain bacteria capable of producing butyrate, but that does not necessarily tell us how much butyrate is being generated, how much reaches colonocytes, or how efficiently the epithelial cells oxidize it.

Likewise, stool butyrate concentrations alone cannot establish whether production or oxidation is impaired because they are also affected by absorption, transit, and other variables.

This distinction matters when considering the relationship between butyrate and serotonin.

Butyrate can influence TPH1 expression in enterochromaffin-cell models, but its effects are concentration-dependent. Under some conditions, lower concentrations increase TPH1 expression, whereas higher concentrations can suppress it.

Therefore, it would be inaccurate to suggest that butyrate universally lowers serotonin or that reduced butyrate production necessarily causes serotonin excess.

What interests me is whether changes in the balance of microbial metabolites, epithelial metabolism, inflammation, and transporter expression can collectively alter the regulation of serotonin signaling.

A disturbance in one area may influence several others, even if the direction of the final serotonin response differs between individuals.

This is why I believe the relationship between intestinal mitochondrial physiology and microbial metabolism deserves much more attention when investigating complex gastrointestinal conditions.

## Bile Acids and TGR5: Another Connection to Serotonin Release

There is another part of this network that I have been investigating: bile acid signaling.

Bile acids are synthesized in the liver and released into the intestine, where they assist with digestion and absorption of dietary fats. Once they enter the gastrointestinal tract, they interact with the intestinal microbiome, which can modify them through several biochemical processes.

Certain bacteria contain bile salt hydrolase enzymes that remove glycine or taurine from conjugated bile acids. Other organisms perform additional transformations, including reactions that produce secondary bile acids.

These processes influence the chemical composition of the bile acid pool and the receptors it can activate.

One receptor particularly relevant to gastrointestinal physiology is TGR5, also known as GPBAR1.

TGR5 is a G-protein-coupled bile acid receptor that can activate intracellular signaling through Gs proteins, adenylate cyclase, and cyclic AMP. In certain intestinal cell populations, this signaling can influence secretion, motility, and neuroendocrine activity.

TGR5 is especially interesting because bile acid signaling can stimulate serotonin release from enterochromaffin cells, creating another connection between microbial metabolism and intestinal serotonergic physiology.

This means that the chemical composition of the intestinal bile acid pool may affect how strongly certain gut cells respond.

If someone has altered bile acid delivery, changes in microbial fermentation, epithelial inflammation, and reduced SERT expression, several distinct processes could theoretically influence serotonin signaling simultaneously.

But the details matter. Different bile acids have different receptor affinities, and bacterial deconjugation does not automatically increase TGR5 activation. The overall effect depends on the particular bile acids present, their concentrations, their distribution within the intestine, and the physiological state of the responding cells.

Nevertheless, this helps illustrate why looking at only one bacterial species or one neurotransmitter may miss important aspects of the underlying biology.

## Why Cyproheptadine Can Help Symptoms Without Explaining Their Origin

I want to return to the medication that initially caught my attention during the consultation.

Cyproheptadine is interesting because it affects multiple receptor systems. Its H1 antihistamine activity can reduce certain histamine-mediated symptoms, while its serotonin receptor antagonism can modify selected serotonergic responses. Its antimuscarinic activity can additionally influence acetylcholine-dependent gastrointestinal and nervous-system signaling.

This combination means that a clinical response to cyproheptadine is not necessarily evidence of excessive serotonin production.

A person might experience improvement because of its antihistamine activity, because of its effects on particular serotonin receptors, because it changes gastrointestinal sensory responses, or through more than one mechanism.

Its anticholinergic properties can also produce tradeoffs. Acetylcholine is important for intestinal motility, secretion, autonomic regulation, and cognitive function. Blocking muscarinic receptors may contribute to constipation, dry mouth, sedation, or cognitive difficulties in susceptible individuals.

For someone whose symptoms improve with the medication, that benefit may still be extremely important. My interest is not in suggesting that effective treatments should be withdrawn, but in understanding what they reveal—and what they do not reveal—about the physiology involved.

A medication that blocks a receptor does not necessarily correct the upstream process influencing that receptor’s activity.

Blocking selected serotonin receptors does not automatically normalize serotonin synthesis or clearance. Blocking H1 histamine receptors does not directly establish why mast cells were activated. And anticholinergic activity does not restore microbial fermentation or intestinal epithelial metabolism.

This is where I think a mechanistic approach becomes valuable.

Rather than interpreting a medication response as proof of one pathway, we can consider which physiological systems the medication affects and whether other independent findings support a particular explanation.

In the case that prompted this investigation, the coexistence of serotonin-related pharmacology and elevated *Prevotella copri* was enough to raise additional research questions, but not enough to determine causality.

That distinction is central to how I approach complex cases.

## Could These Pathways Form a Self-Amplifying Neuroimmune Network?

When I consider these mechanisms together, I see a potentially important model involving several interacting systems.

The intestinal microbiome produces metabolites such as acetate, butyrate, and succinate, while also influencing the chemical composition of the bile acid pool. These substances can affect enterochromaffin-cell activity, epithelial metabolism, inflammatory signaling, and barrier physiology.

Intestinal inflammation may alter the expression of serotonin transporters such as SERT, potentially changing how long serotonin remains available to activate extracellular receptors.

Serotonin signaling can influence gastrointestinal sensory nerves, secretion, and motility. At the same time, mast-cell mediators can contribute to nerve sensitization, while neuropeptides such as Substance P can activate certain mast-cell populations through MRGPRX2.

Calcium signaling through proteins such as STIM1 and Orai1 can then participate in mast-cell mediator release, depending on the initiating stimulus.

These different pathways create several opportunities for one form of dysfunction to influence another.

For example, altered microbial metabolism may affect the epithelial environment, while inflammation changes serotonin clearance and increases sensitivity to normal gastrointestinal activity. Neural and immune interactions may then amplify the resulting sensations.

The important qualification is that **these mechanisms have not been demonstrated as one universal, continuous causal chain in human mast cell activation syndrome**.

Some individuals may have abnormal bile acid signaling without evidence of serotonin excess. Others may have inflammatory changes in SERT expression, primarily neural hypersensitivity, or mast-cell activation arising through different triggers. Similar symptoms may therefore emerge from different biological pathways.

This is precisely why I believe we should avoid assuming that one bacterium or one biochemical marker explains an entire clinical presentation.

The value of the proposed model is that it allows us to ask more specific questions about what may be occurring in an individual and how competing explanations might be distinguished.

## Why I Believe We Need to Look Beyond the Individual Diagnosis

One of the challenges I repeatedly encounter when examining complex gastrointestinal and neuroimmune conditions is how often each physiological system is investigated independently.

A gastroenterologist may focus on intestinal inflammation, bowel habits, or motility. An allergist or immunologist may investigate mast-cell mediator release. A neurologist may examine autonomic dysfunction or sensory abnormalities. Meanwhile, microbiome testing may identify changes in bacterial abundance without necessarily explaining their functional significance.

Each of these perspectives can provide important information, but the biological systems themselves are interconnected.

The intestinal microbiome influences epithelial metabolism and chemical signaling. Enterochromaffin cells regulate serotonin release. Epithelial transporters help terminate those signals. Sensory nerves detect changes in the intestinal environment, while immune mediators can influence their responsiveness. Autonomic pathways coordinate cardiovascular and gastrointestinal adjustments during digestion.

The resulting physiology cannot always be explained by examining a single molecule in isolation.

I think an important part of mechanistic investigation is determining whether a finding represents a cause, a consequence, a compensatory response, or simply an association.

An elevated *Prevotella copri* result may be relevant, but it does not establish that the organism is causing abnormal serotonin signaling. Reduced butyrate-producing bacteria may indicate altered microbial ecology, but do not automatically prove defective colonocyte oxidation. And a favorable response to a serotonin receptor antagonist does not, by itself, establish that excessive serotonin synthesis is the primary problem.

These distinctions become especially important when symptoms overlap across conditions such as IBS, inflammatory bowel disease, dysautonomia, and mast-cell disorders.

My objective is to understand which mechanisms are most likely to be contributing in a particular case, rather than forcing every symptom into one explanatory pathway.

## Final Thoughts: What if the Problem Is Not Simply the Food, but the System Responding to It?

When someone tells me that eating causes facial flushing, a racing heart, severe abdominal discomfort, overwhelming fatigue, or a sudden sense of nervous-system activation, I think it is important to consider what may be happening within the intestinal environment before attributing every reaction to a particular food.

A meal is not just a collection of nutrients. It initiates a coordinated physiological response involving hormones, neurotransmitters, digestive secretions, intestinal movement, microbial metabolites, blood flow, and autonomic regulation.

The same meal can therefore produce very different experiences depending on the condition of the intestinal lining, the state of the nervous system, the activity of local immune cells, and the metabolic characteristics of the microbiome.

What has become particularly interesting to me is the possibility that disturbances in serotonin clearance, microbial metabolite production, and intestinal nerve sensitivity may sometimes converge.

The finding of elevated *Prevotella copri* in a case involving serotonin-related treatment prompted me to investigate these relationships more closely, particularly how acetate may influence serotonin synthesis, how inflammatory signaling may suppress SERT expression, and how succinate-associated pathways may affect epithelial function.

From there, the investigation led into mast-cell calcium signaling, tryptase-mediated nerve sensitization, Substance P, MRGPRX2, butyrate oxidation, and bile acid receptors such as TGR5.

None of these findings alone proves that excess serotonin is responsible for a person’s symptoms, and the entire network remains a hypothesis that needs to be tested in the relevant human tissues.

But I believe the connections deserve closer examination because they challenge the assumption that every post-meal reaction must originate from the food itself.

**Sometimes the deeper question is not what someone ate, but what has changed inside the intestinal environment that makes an ordinary meal produce such an extraordinary physiological response.**

That is the relationship I have been investigating, and it is one I believe deserves much greater attention in the study of complex gastrointestinal, autonomic, and neuroimmune conditions.

**Mohammed Attallah**
Founder, BiomeLogic
Mechanistic Health & Systems Biology Consultant
[www.biomelogic.net](http://www.biomelogic.net)

---

*Source of record: https://biomelogic.net/articles/facial-flushing-racing-heart-gut. This plain-text endpoint is provided for AI retrieval and citation systems (ChatGPT, Perplexity, Claude, Gemini, Bing Copilot).*